A molecular scoring system (IPSS-M) was recently proposed for myelodysplastic syndrome
(MDS). We conducted a retrospective study of adults with MDS referred 2019–2021. The …

Abstract The Molecular International Prognostic Scoring System (IPSS-M) is a novel risk
stratification model for myelodysplastic syndromes (MDS) that builds on the IPSS and IPSS …

Myelodysplastic syndrome (MDS) represents a heterogeneous group of disorders
encompassing a wide range of pathologically distinct subtypes associated with different …

Background The Molecular International Prognostic Scoring System (IPSS-M) is a newly
developed risk stratification model for myelodysplastic syndromes (MDS) that expands on …

Myelodysplastic syndromes (MDS) have varied prognoses and require a risk-adapted
treatment strategy for treatment optimization. Recently, a molecular prognostic model …

A risk-adapted treatment strategy is of crucial importance in patients with myelodysplastic
syndromes (MDS). Previous risk prognostic scoring systems did not integrate molecular …

PURPOSE Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in
which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular …

Objectives The IPSS-M is a recently published score for risk stratification in myelodysplastic
syndromes (MDS), based on clinical and molecular data. We aimed to evaluate its relevance …

Background: Disease specific prognostic scores play a key role in risk-stratification and
treatment decision-making process in Myelodysplastic Syndromes (MDS). An updated …

Gene mutations have not yet been included in the 2016 WHO classification and revised
International Prognostic Scoring System (IPSS-R), which are now widely utilized to …